Phase IIa trial of ASC30, a once-monthly GLP-1 agonist for obesity Novo Nordisk's oral semaglutide (Rybelsus) has become the first FDA-approved oral GLP-1 therapy to reduce major cardiovascular events in high-risk type 2 diabetes patients Clearmind Medicine filed a U.S
While it's gained significant attention in the wellness and beauty communities for its potential skin benefits, there's considerable confusion about how it works, appropriate dosages, and whether it truly delivers on its promises
It all comes down to careful handling and understanding the initial concentration of your raw material
Discuss timing options with your provider, and keep a symptom log for one to two weeks after any change to assess whether the adjustment helps
Unfortunately, in my experience, this message isn't often highlighted to people on (or considering taking) GLP-1 for weight loss
It has not been stringently monitored for contaminants that can harm the user, so it is potentially unsafe and not to be used as a therapeutic drug
